ParcelBio
YC W24San Francisco, US · Founded 2023 · Delaware corporation · 6 employees · 11 known investors
ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
Also known as Parcel Therapeutics · Parcel Therapuetics
AI & Machine LearningBiotechDeep TechHealthtechGene TherapySynthetic BiologyTherapeuticsDrug discoveryUnited States of AmericaAmerica / Canada
Founders & leadership· Y Combinator alumni (W24)
ParcelBio was founded in 2023 by David Weinberg and Chris Carlson.
DW
David WeinberginCo-Founder and CEOHe previously held VP-level roles at Orbital Therapeutics/Circ Bio leading RNA platform development and at Freenome as Sr. Director of Molecular Research building multiomics diagnostics capabilities. He holds a PhD from MIT and was a UCSF Faculty Fellow.
CC
Chris CarlsoninCo-Founder and CSOHe previously worked as a scientist at Orbital Therapeutics, where he contributed to patents on RNA stabilization, and holds a PhD in RNA virology from UCSF.
Board
MC
Investors · 11
Y Combinator✓ verifiedSan Francisco · $500K
Breyer Capital✓ verifiedAustin · $500K – $10M
.png)
General Catalyst✓ verifiedSan Francisco · $30M
Lexi VenturesSan Francisco
MetaplanetTallinn · $500K – $10M
North South VenturesToronto
Ritual CapitalMenlo Park · $100K – $500Kvia Chris Howard · inferred
Spacecadet VenturesKent County · $100K – $500K
ZAKA VCSan Francisco
468 CapitalreportedBerlin
Also in the syndicate · 1
SurgePoint Capital
Reported raises · per SEC filings
Form D private placements$13.2M disclosed across 1 round · 2026
▶$13.2MraisedMar 2026 · 52 investors · BiotechnologyRule 506(c)
▶$13.2MraisedMar 2026 · 52 investors · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Morgan CheathamDirector
- Christopher CarlsonExecutive Officer, Director
- David WeinbergExecutive Officer, Director
- Offering amount
- $13.2M
- Amount sold
- $13.2M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06c
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 8
by search overlap
Eclipse Bio11 shared keywordsEclipsebio provides RNA biology analytical services and sequencing-based assays that help drug developers and researchers characterize RNA at nucleotide-level resolution and generate datasets for AI-driven drug discovery. It serves pharma, biotech, and academic partners working on oligonucleotides, RNA-targeting small molecules, and fundamental RNA research.
Senti Biosciences10 shared keywordsSenti Bio develops cell and gene therapies for cancer and difficult-to-treat diseases using synthetic biology and engineered Gene Circuits to enhance precision, control, and selectivity in targeting tumor cells. The company is a clinical-stage biotech firm leveraging proprietary platform technology across multiple cell types and modalities.
Dispatch Biotherapeutics10 shared keywordsDispatch Bio develops a universal immunotherapy treatment for solid tumors, combining engineered immunotherapy with a tumor-specific virus to improve cancer treatment outcomes.
Splice Bio10 shared keywordsSpliceBio develops genetic medicines using a proprietary protein splicing platform to treat diseases caused by mutations in large genes. The company is currently in clinical stages, with its lead program targeting Stargardt Disease.
Precision BioSciences9 shared keywordsPrecision BioSciences develops gene-editing medicines using its proprietary ARCUS genome editing platform, which employs sequence-specific nuclease enzymes to insert, remove, or repair DNA in living cells to treat hard-to-treat conditions including rare genetic diseases and hepatitis B (HBV).
Mission Bio9 shared keywordsMission Bio develops single-cell biology tools and platforms for researchers and clinicians to enable precision medicine discovery and cancer treatment. The company serves the biomedical research and clinical diagnostics market.
Bridgebio8 shared keywordsBridgeBio develops treatments for genetic conditions and cancers using a decentralized hub-and-spoke model, where autonomous teams focus on specific diseases or drug candidates while a central hub provides clinical, regulatory, and commercial support. The company partners with academic institutions to advance early-stage research toward late-stage clinical trials.
AskBio8 shared keywordsAskBio is a gene therapy company developing adeno-associated virus (AAV)-based genetic medicines for rare and other diseases, with clinical programs such as AB-1009 for late-onset Pompe disease. It operates as a wholly owned, independent subsidiary of Bayer AG.
Companies competing with ParcelBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does ParcelBio do?
- ParcelBio develops APEXm, a proprietary mRNA platform that enhances protein expression for longer-lasting therapeutic effect compared to conventional mRNA technologies. The platform targets autoimmune disease, oncology, and therapeutic protein replacement applications.
- Who founded ParcelBio?
- ParcelBio was founded by David Weinberg, Chris Carlson in 2023.
- Who are ParcelBio's investors?
- ParcelBio's investors include Y Combinator, Breyer Capital, General Catalyst, Lexi Ventures, Metaplanet, North South Ventures, Ritual Capital, Spacecadet Ventures and 2 more.
- How much funding has ParcelBio raised?
- ParcelBio has disclosed $13.2M raised across 1 round.
- Where is ParcelBio headquartered?
- ParcelBio is headquartered in San Francisco, US.